Dare Bioscience ($DARE)

Stock Image

DARE Overview

Daré Bioscience, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States.The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single application; Ovaprene, a non-hormonal monthly contraceptive intravaginal ring; and Sildenafil Cream, a cream formulation of sildenafil to treat female sexual arousal disorder.The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone replacement therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and for fertility support in an in vitro fertilization treatment plan.Its products in pre-clinical stage include DARE-RH1, a non-hormonal contraception for men and women; ORB-204 and ORB-214 that are formulations of injectable etonogestrel for contraception; and a microchip-based implantable drug delivery system to provide contraception.The company has license agreement with ADVA-Tec, Inc. to develop and commercialize Ovaprene for human contraceptive use; and license and collaboration agreement with Strategic Science & Technologies-D, LLC and Strategic Science & Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health.Daré Bioscience, Inc. is headquartered in San Diego, California. (From: StockAnalysis.com)

MORE ABOUT Dare Bioscience

Stay up to date with the best of Bullish each week.


Stay up to date with the best of Bullish each week.